Viemed (VMD) Q2 2026 Earnings Call Transcript
Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY 2026 revenue guidance and updated adjusted EBITDA range, alongside cash flow and capex guidance changes that inform the growth-to-cash conversion narrative.
Market read
Record ventilator patient counts and a raised FY revenue outlook are the primary positive catalysts, while adjusted EBITDA margin compression and temporary integration costs temper the earnings quality signal.
What to watch
The article attributes EBITDA margin compression to prior-year nonrecurring gains and temporary costs, so traders should watch whether compliance, qualification time reductions, and in-house call center changes continue to improve unit economics into subsequent quarters.
Background
Viemed Healthcare’s Q2 2026 call covers ventilation rental growth plus expansion in sleep therapy and maternal health, with CMS national coverage determination and workflow automation cited as key drivers.
Ticker impact
Viemed reported Q2 2026 revenue of $78.1M, raised FY 2026 revenue guidance to $314M-$320M, and revised adjusted EBITDA guidance to $64M-$68M.
Near-term bias modestly positive on the guidance raise, tempered by adjusted EBITDA margin compression and temporary integration and SG&A costs.
The article provides multiple hard datapoints: record ventilator patients (12,635), raised revenue guidance, revised EBITDA range, and lower net capex guidance, but also notes adjusted EBITDA margin compression tied to nonrecurring prior-year gains and temporary maternal health and sleep/resupply integration costs.
Market effects
Highlights demand and reimbursement-driven dynamics in at-home ventilation and sleep therapy, with CMS coverage standards cited as a growth driver.
No specific regional market impact disclosed beyond US Medicare/CMS context.
Primarily US reimbursement and healthcare services, limited direct global market linkage.
Counterpoint
Raised revenue guidance may not translate to sustained EBITDA margin if temporary integration and maternal health supply transitions persist longer than management implies.
Key entities
- public_companyViemed Healthcare, Inc.
Reported Q2 2026 results and updated FY 2026 guidance, including raised revenue and revised adjusted EBITDA and net capex ranges.
- executiveCasey Hoyt
CEO who attributed ventilator growth to adaptation to CMS qualification and utilization standards and discussed workflow improvements.
- executiveTrae Fitzgerald
CFO who presented financial results and guidance ranges on the earnings call.
- executiveTodd Zehnder
Commented on risks and drivers behind EBITDA comparisons and temporary costs in maternal health and sleep/resupply operations.
